NCT07837830RecruitingEarly phase 1
Early Intervention With Inhaled Treprostinil Among Patients With Exercise-Induced Pulmonary Hypertension (EPIH)
Early Intervention With Inhaled Treprostinil Among Patients With Exercise-Induced Pulmonary Hypertension: A Prospective Open-Label Matched Control Pilot Trial.
Source: ClinicalTrials.gov · Last updated 24 Sept 2026
Brief summary (registry, in English)
This prospective open-label matched-control pilot study evaluates whether inhaled treprostinil improves exercise pulmonary vascular resistance and functional outcomes in adults with interstitial lung disease or connective tissue disease and exercise-induced pulmonary hypertension. Participants will receive inhaled treprostinil plus standard care or standard care alone and will be followed for 6 months, with an optional extension to 12 months.
- Status (registry)
- Recruiting
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 32 (estimated)
- First submitted
- 10 Sept 2026
- Start date
- Sept 2026
- Primary completion date
- Dec 2027
- Lead sponsor
- Valley Health System
- NCT number
- NCT07837830
What you commit to
- Study type: Interventional · Early phase 1
- Planned participants: 32
- From Sept 2026 to the primary completion date, Dec 2027
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current PAH-targeted therapy
Other illness
- Resting pulmonary hypertension
- Significant left heart disease
- Severe renal or hepatic impairment
- Treprostinil hypersensitivity
Other
- CTEPH
- Acute PE within 6 months
- Pregnancy or breastfeeding
- Inability to perform exercise testing
- Contraindication to RHC
Who the study is looking for
- Age ≥18 years
- ILD diagnosis or CTD diagnosis
- WHO Functional Class II-III
- Resting RHC:
- mPAP ≤20 mmHg
- PVR ≤2 WU
- PAWP ≤15 mmHg
- Exercise-induced pulmonary hypertension on iCPET
- Able to provide informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Valley Hospital Coordinator of this site? Confirm its status | Paramus | United States | Recruiting |
| Valley Medical Group Pulmonary Hypertension Clinic Coordinator of this site? Confirm its status | Paramus | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.